Leigh Brody

Investment Manager, UCL Technology Fund

2021 - Current

The UCL Technology Fund is managed by AlbionVC and is dedicated to investing in the next generation of life-changing innovative technologies, arising from UCL's world-class research base.

Board Director

2022

Bloomsbury Genetic Therapies is a spin-out from University College London (UCL), emerging from the world-leading gene therapy and rare diseases expertise of our academic founders, Prof Paul Gissen, Prof Manju Kurian, Prof Ahad Rahim and Prof Simon Waddington, in collaboration with UCL Business. It's mission is bringing potentially curative treatments to patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies.

Member and Angel Investor

2022

Executive Director of Platform Strategy

2019 - 2020

Chief Scientific Officer

2017 - 2019

Director of Genomics

2015 - 2017

Founder

2012 - 2014

Founder of a spin-out from my PhD, developing lipid-based nanoparticles (LNPs) for small molecule and mRNA delivery solutions.

Life Science Investor

2013 - 2014

Research Technician II

2005 - 2008

The RNAi Consortium (TRC) - TRC1, 1.5, 2 and Project Achilles.